Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
The company will start its confirmatory bexobrutideg study in June.
Circle Pharma and Verismo feature in coveted sessions.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Talapro-3 could help move Talzenna into earlier prostate cancer.
